Metformin for FSGS: A phase 1/2 trial
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether the diabetes drug metformin can help people with a kidney disease called FSGS, by activating a cell-protecting pathway. Participants will take metformin or a placebo along with their usual steroid treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old
- You must have a confirmed diagnosis of primary FSGS from a kidney biopsy
- Your doctor must be planning to treat you with steroids or similar immune medicines
- You must not have diabetes or be taking diabetes medications
- Your kidney function must be at least 32 (eGFR)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
This study tests if a type 2 diabetes medication (SGLT2 inhibitor) can help people with frequent gout flares. It aims to lower uric acid levels and reduce flare-ups.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.